The 72-week trial duration in SURMOUNT studies was not arbitrary
If semaglutide made up 80% of GLP-1 volume (before Zepbound), that implies compounded share closer to 32% (source) Now, look at Hims: They launched compounded semaglutide in Q2 2024 and reported $225M in GLP-1 revenue through year-end (source)
This demands a structured, comprehensive program, fellowship training, and high-volume centers for safe and effective medical weight loss
Some general measures help alongside this medicine, especially for the liver
This is especially important as newer and more potent drugs are on the horizon for obesity management
Statistical analysis Statistical analyses of the clinical data were performed using Fishers exact probability test, Students t test, and a paired t test